2nd Quarter - Report

340B HEALTH for 340B HEALTH

Firm
Client
Income
—
Expenses
$272,268
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

The 340B Drug Pricing Program; S.773 - A bill to enable certain hospitals that were participating in or applied for the drug discount program under section 340B of the Public Health Service Act prior to the COVID-19 public health emergency to temporarily maintain eligibility for such program, and for other purposes; H.R. 853: Closing Loopholes for Orphan Drugs Act; H.R.3203 - To enable certain hospitals that were participating in or applied for the drug discount program under section 340B of the Public Health Service Act prior to the COVID-19 public health emergency to temporarily maintain eligibility for such program, and for other purposes; H.R.3 - Elijah E. Cummings Lower Drug Costs Now Act; H.R.19 - Lower Costs, More Cures Act of 2021;

LobbyistCovered position, as disclosed
ELISE CRANSTON —
KATHRYN DIBITETTO —
GREG DOGGETT —
KATE ILAHI —
AMANDA SELLERS SMITH —
MAUREEN TESTONI —

Contacted: Health & Human Services, Dept of (HHS); Health Resources & Services Administration (HRSA); SENATE; HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 3203 (117th), S. 773 (117th), H.R. 853 (117th), H.R. 3 (117th), H.R. 19 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.